Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

BACKGROUND: Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and high plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, Andrew James, Ferris, Peter, Bradbury, Ian, Conlon, John, Shankar-Hari, Manu, Rogers, Angela J., O’Kane, Cecilia M., McAuley, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175337/
https://www.ncbi.nlm.nih.gov/pubmed/35672834
http://dx.doi.org/10.1186/s13054-022-04025-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175337/
https://www.ncbi.nlm.nih.gov/pubmed/35672834
http://dx.doi.org/10.1186/s13054-022-04025-w

Ejemplares similares